Table 1. Comparison of baseline clinical parameters between NSCLC patients with or without liver metastasis.
| With de novo liver metastasis (n = 75) |
Without de novo liver metastasis (n = 415) |
P value | |
|---|---|---|---|
| Age, years | 61.8 ± 12.4 | 64.2 ± 12.3 | 0.130 |
| BMI | 22.5 ± 3.5 | 22.9 ± 3.9 | 0.428 |
| Sex | 0.062 | ||
| Male | 29 (38.7) | 209 (50.4) | |
| Female | 46 (61.3) | 206 (49.6) | |
| DM | 0.835 | ||
| Yes | 8 (10.7) | 41 (9.9) | |
| No | 67 (89.3) | 374 (90.1) | |
| Smoking history | 0.082 | ||
| Never | 54 (72.0) | 255 (61.4) | |
| Former / current | 21 (28.0) | 160 (38.6) | |
| Performance status | 0.443 | ||
| ECOG 0–2 | 66 (88.0) | 377 (90.8) | |
| ECOG 3–4 | 9 (12.0) | 38 (9.2) | |
| EGFR mutation | 0.435 | ||
| Yes | 39 (52.0) | 236 (56.9) | |
| No | 36 (48.0) | 179 (43.1) | |
| Tumor type | 0.758 | ||
| Adenocarcinoma | 65 (86.7) | 354 (85.3) | |
| Non-adenocarcinoma | 10 (13.3) | 61 (14.7) | |
| LMR > 3.1 | 30 (40) | 231 (55.7) | 0.002 |
| Brain metastasis | 25 (33.3) | 99 (23.9) | 0.083 |
| Bone metastasis | 48 (64.0) | 197 (47.5) | 0.008 |
| Pleural metastasis | 22 (29.3) | 179 (47.5) | 0.025 |
BMI, body-mass index; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LMR, lymphocyte-to-monocyte ratio; NSCLC, non-small-cell lung cancer.